Emerging and Novel Treatments for Pituitary Tumors

• Main Authors: Mirela Diana Ilie, Hélène Lasolle, Gérald Raverot
• Format: Article
• Language: English
• Published: MDPI AG 2019-07-01
• Series: Journal of Clinical Medicine
• Subjects: pituitary neuroendocrine tumors (PitNETs); pituitary adenoma; aggressive pituitary tumors; treatment; temozolomide; peptide receptor radionuclide therapy; bevacizumab; tyrosine kinase inhibitors; everolimus; immunotherapy
• Online Access: https://www.mdpi.com/2077-0383/8/8/1107

A subset of pituitary neuroendocrine tumors (PitNETs) have an aggressive behavior, showing resistance to treatment and/or multiple recurrences in spite of the optimal use of standard therapies (surgery, conventional medical treatments, and radiotherapy). To date, for aggressive PitNETs, temozolomide (TMZ) has been the most used therapeutic option, and has resulted in an improvement in the five-year survival rate in responders. However, given the fact that roughly only one third of patients showed a partial or complete radiological response on the first course of TMZ, and even fewer patients responded to a second course of TMZ, other treatment options are urgently needed. Emerging therapies consist predominantly of peptide receptor radionuclide therapy (20 cases), vascular endothelial growth factor receptor-targeted therapy (12 cases), tyrosine kinase inhibitors (10 cases), mammalian target of rapamycin (mTOR) inhibitors (six cases), and more recently, immune checkpoint inhibitors (one case). Here, we present the available clinical cases published in the literature for each of these treatments. The therapies that currently show the most promise (based on the achievement of partial radiological response in a certain number of cases) are immune checkpoint inhibitors, peptide receptor radionuclide therapy, and vascular endothelial growth factor receptor-targeted therapy. In the future, further improvement of these therapies and the development of other novel therapies, their use in personalized medicine, and a better understanding of combination therapies, will hopefully result in better outcomes for patients bearing aggressive PitNETs.